化瘀通络方联合多西他赛加顺铂化疗方案治疗非小细胞肺癌的临床研究

Effects of Huayu Tongluo Formula combined with docetaxel plus cisplatin chemotherapy regimen on non-small cell lung cancer

目的观察化瘀通络方联合多西他赛加顺铂(DP)化疗方案治疗非小细胞肺癌(NSCLC)的临床疗效。方法选取2019年4月至2021年10月收治的128例NSCLC患者作为研究对象,按照随机数字表法分为2组,对照组67例予DP化疗方案治疗,治疗组61例在对照组治疗基础上联合化瘀通络方治疗。2组均治疗1个疗程后统计疗效,比较2组治疗前后中医症状(包括咳嗽咯痰、咳嗽带血、气短乏力及胸闷胸痛)评分、免疫功能指标(包括T淋巴细胞亚群CD3^(+)、CD4^(+)及CD8^(+))及肿瘤病人生活质量评分(QOL)(包括生理、情感、功能、家庭/社会以及附加关注5个维度)变化情况,比较2组治疗期间不良反应发生情况。结果治疗组总有效率81.97%(50/61),不良反应总发生率14.75%(9/61),对照组总有效率65.67%(44/67),不良反应总发生率16.42%(11/67),治疗组总有效率高于对照组(P<0.05),但2组不良反应总发生率组间比较差异无统计学意义(P>0.05)。与本组治疗前比较,2组治疗后中医症状咳嗽咯痰、咳嗽带血、气短乏力及胸闷胸痛评分均降低(P<0.05),且治疗组治疗后中医症状咳嗽咯痰、咳嗽带血、气短乏力及胸闷胸痛评分均低于对照组(P<0.05)。与本组治疗前比较,治疗组治疗后T淋巴细胞亚群CD3^(+)、CD4^(+)及CD8^(+)水平均升高(P<0.05),且治疗组治疗后T淋巴细胞亚群CD3^(+)、CD4^(+)及CD8^(+)水平均高于对照组(P<0.05)。对照组治疗前后T淋巴细胞亚群CD3^(+)、CD4^(+)及CD8^(+)水平比较差异均无统计学意义(P>0.05)。与本组治疗前比较,2组治疗后QOL量表生理、情感、功能、家庭/社会以及附加关注评分均升高(P<0.05),且治疗组治疗后QOL量表生理、情感、功能、家庭/社会以及附加关注评分均高于对照组(P<0.05)。结论化瘀通络方化瘀通络方联合DP化疗方案治疗NSCLC疗效确切,可有效改善患者中医症状,提高患者免疫功能,改善生活质量,且安全可靠。

Objective To explore the effects of Huayu Tongluo Formula combined with docetaxel plus cisplatin(DP)chemotherapy regimen in the treatment of non-small cell lung cancer(NSCLC).Methods From April 2019 to October 2021,a total of 128 patients with NSCLC were randomly assigned into the treatment group(n=61)and the control group(n=67).All patients were given DP chemotherapy,and patients in the treatment group were additionally given Huayu Tongluo Formula,the curative effects of the two groups were statistically analyzed after 1 course of treatment.The key observation was traditional Chinese medicine(TCM)symptoms(cough and expectoration,cough with blood,shortness of breath and fatigue,chest tightness and chest pain)scores,immune function indexes(T lymphocyte subsets:CD3^(+),CD4^(+)and CD8^(+))and quality of life scores(QOL)(five dimensions of physiology,emotion,function,family/society and additional attention)between the two groups before and after treatment,as well as treatment-emergent adverse events(TEAEs).Results The total effective rate in the treatment group was better than that of the control group(81.97%[50/61]vs 65.67%[44/67],P<0.05).The difference was not statistically significant in the total incidence of adverse reactions between the treatment group and the control group(14.75%[9/61]vs 16.42%[11/67],[P>0.05],respectively).After treatment,the TCM symptoms scores in the two groups were significantly decreased(P<0.05),and the decrease in the treatment group was more pronounced(P<0.05).Compared with before treatment,the levels of T lymphocyte subsets(CD3^(+),CD4^(+)and CD8^(+))in the treatment group were significantly increased after treatment(P<0.05),and which in the treatment group were significantly higher than the control group(P<0.05).While,there was no significant difference in the levels of T lymphocyte subsets(CD3^(+),CD4^(+)and CD8^(+))in the control group before and after treatment(P>0.05).The QOL scores in the two groups were significantly increased(P<0.05),and the increase in the treatment group was more obvious(P<0.05).Conclusion Huayu Tongluo Formula combined with DP chemotherapy regimen in the treatment of NSCLC is effective,it can significantly improve TCM symptoms,immune function,and quality of life,and it is safe and reliable.